Details of the Drug

General Information of Drug (ID: DMKAIR9)

Drug Name

AZD9574

Synonyms

AZD-9574; AZD9574; 2756333-39-6; 9UG32UQW48; UNII-9UG32UQW48; 2-Pyridinecarboxamide, 6-fluoro-5-(4-((5-fluoro-3,4-dihydro-2-methyl-3-oxo-6-quinoxalinyl)methyl)-1-piperazinyl)-N-methyl-; 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide; 6-fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide; CHEMBL5095223; SCHEMBL24156588; GTPL11946; GLXC-25685; EX-A6177; NSC840950; AKOS040759967; AT34947; NSC-840950; example 20 [WO2021260092A1]; MS-27579; HY-145804; CS-0433406; 6-FLUORO-5-(4-((5-FLUORO-2-METHYL-3-OXO-3,4-DIHYDROQUINOXALIN-6-YL)METHYL)PIPERAZIN-1-YL)-N-METHYLPICOLINAMIDE

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C21H22F2N6O2
Canonical SMILES: CC1=NC2=C(C(=C(C=C2)CN3CCN(CC3)C4=C(N=C(C=C4)C(=O)NC)F)F)NC1=O
InChI: InChI=1S/C21H22F2N6O2/c1-12-20(30)27-18-14(25-12)4-3-13(17(18)22)11-28-7-9-29(10-8-28)16-6-5-15(21(31)24-2)26-19(16)23/h3-6H,7-11H2,1-2H3,(H,24,31)(H,27,30)
InChIKey: WXRCLFFPZXJCLS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 162524593
TTD ID: DC23ER

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Poly [ADP-ribose] polymerase (PARP)	TTEBCY8	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05417594) A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of AstraZeneca